Treatment of pediatric non‐Hodgkin lymphoma in Hungary: 15 years experience with NHL‐BFM 90 and 95 protocols

Abstract

Retrospective analysis was performed to assess the survival-rates of children with non-Hodgkin lymphoma (NHL), treated according to the NHL-BFM (Berlin-Frankfurt-Münster)-90 and -95 protocols between 1990 and 2004 in Hungary, and to compare our data with the international results. Ninety-one patients had non-B-NHL, 108 B-NHL, and 31 ALCL. Complete remission rate was 89%, while 12% relapsed later. The 5-year-overall-survival was 78% and the event-free survival was 75%. These results are lower than those reported by the BFM study group, but comparable from other European centers. In the last 5 years, the results showed 10% improvement and death during induction was reduced from 10 to 3%.

Limited stage I disease is not necessarily indicative of an excellent prognosis in childhood anaplastic large cell lymphoma

“…The present data show that limited stage I ALCL disease has an incidence of 8%, which is in the same range as in other available studies. 4,5,[7][8][9]19 Although the number of patients identified was rather low, the present study showed that initially completely resected stage I ALCL has a good prognosis with 3 courses of chemotherapy; however, patients with stage I disease and no complete resection had a relapse rate of 30% at 5 years, which was no better than the rate observed in patients with stage II or stage III/IV disease. Because a new site of disease involvement was found in all cases at For personal use only.…”

The efficacy of rituximab in high-grade pediatric B-cell lymphoma/leukemia: a review of available evidence

“…The 10 patients with mature B-cell ALL/NHL with complete data are summarized in Table 1 [9,[11][12][13][15][16][17]. Data available on the remaining nine patients include diagnosis, disease state at time of therapy and survival [10]. All nine patients had B-cell NHL, were treated on Berlin-Frankfurt-Munster (BFM)-90 and 95 protocols and received rituximab for relapsed (four) or refractory disease (five).…”

“…In a thorough review of the literature, including a query directed at the manufacturer, we found 19 cases of children with high-grade B-lineage disease who received rituximab, alone or in combination with chemotherapy, as salvage therapy [8][9][10][11][12][13][14][15]. The 10 patients with mature B-cell ALL/NHL with complete data are summarized in Table 1 [9,[11][12][13][15][16][17].…”

Lymphomák adoleszcens korban: Érdemes-e gyermek-protokollal kezelni ezt a betegcsoportot?

“…Az 1988-1998 közö i időszakban a 0-15 éves korosztály OS-e 5 évnél 95%, 10 évnél 92% volt. A NHL-val szereze i honi tapasztalataink szerint a magyar gyermekek túlélési mutatói nem térnek el lényegesen a nemzetközi adatoktól (19). Az 1990-2004 közö i időszakban a NHL-BFM protokollokkal kezelt 0-18 éves NHL-ban szenvedő gyermekek OS-e 5 évnél 78% volt.…”